Incyte Falls on Study Failure, Dermatology Pipeline Sparks Hope

(Bloomberg) -- Incyte Corp. tumbled 12% Friday, the most since April 2018, after the biopharmaceutical company’s itacitinib failed a Phase 3 study for treatment of acute graft-versus-host disease.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.